Literature DB >> 28383646

irRECIST and iRECIST: the devil is in the details.

J Le Lay1, H Jarraya2, L Lebellec3, N Penel1,4.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28383646     DOI： 10.1093/annonc/mdx168

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.

Authors:  Ruitao Lin; Robert L Coleman; Ying Yuan
Journal:  J Natl Cancer Inst       Date:  2020-01-01       Impact factor: 13.506

Review 2.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

3.  Advancing Drug Development in Gynecologic Malignancies.

Authors:  Julia A Beaver; Robert L Coleman; Rebecca C Arend; Deborah K Armstrong; Sanjeeve Bala; Gordon B Mills; Anil K Sood; Thomas J Herzog
Journal:  Clin Cancer Res       Date:  2019-05-24       Impact factor: 12.531

4.  Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer.

Authors:  Meixia Chen; Jing Nie; Yang Liu; Xiang Li; Yan Zhang; Malcolm V Brock; Kaichao Feng; Zhiqiang Wu; Xiaolei Li; Lu Shi; Suxia Li; Mingzhou Guo; Qian Mei; Weidong Han
Journal:  Int J Cancer       Date:  2018-04-26       Impact factor: 7.396

5.  Toward radiomics for assessment of response to systemic therapies in lung cancer.

Authors:  Shawn Sun; Florent L Besson; Binsheng Zhao; Lawrence H Schwartz; Laurent Dercle
Journal:  Oncotarget       Date:  2020-12-22

6.  Editorial to the Special Issue Entitled "Imaging in Immunooncology".

Authors:  Gilbert O Fruhwirth; Bettina Weigelin; Heike E Daldrup-Link; Vladimir Ponomarev
Journal:  Mol Imaging Biol       Date:  2022-04       Impact factor: 3.488

7.  Elevated tumor markers for monitoring tumor response to immunotherapy.

Authors:  Yi Yang; Xiaolin Jiang; Yun Liu; Huan Huang; Yanli Xiong; He Xiao; Kan Gong; Xuemei Li; Xunjie Kuang; Xueqin Yang
Journal:  EClinicalMedicine       Date:  2022-04-08

8.  Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.

Authors:  E Lopci; R J Hicks; A Dimitrakopoulou-Strauss; L Dercle; A Iravani; R D Seban; C Sachpekidis; O Humbert; O Gheysens; A W J M Glaudemans; W Weber; R L Wahl; A M Scott; N Pandit-Taskar; N Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-04       Impact factor: 10.057

Review 9.  Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy.

Authors:  Davide Ippolito; Cesare Maino; Maria Ragusi; Marco Porta; Davide Gandola; Cammillo Talei Franzesi; Teresa Paola Giandola; Sandro Sironi
Journal:  World J Clin Oncol       Date:  2021-05-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.